<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839044</url>
  </required_header>
  <id_info>
    <org_study_id>15/571</org_study_id>
    <nct_id>NCT02839044</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes</brief_title>
  <acronym>Vitacal</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial calcification is an independent predictor of coronary events associated with a 3-4
      fold increased risk of cardiovascular events. Currently, no effective intervention exists to
      reduce arterial calcification. However, recent studies showed that vitamin K may reduce
      ongoing calcium deposition in the arteries, and thereby inhibit arterial calcification.

      The primary objective is to determine if MK-7 supplementation leads to stabilization or
      attenuation of ongoing calcium deposition in the femoral artery as quantified by 18F-NaF
      PET/CT imaging in patients with type 2 diabetes and arterial disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in ongoing calcium deposition quantified as volumetric bone metabolic rate (CSUVMEAN x cm3) in the femoral artery between baseline and 6 months after baseline, as determined by 18F-NaF PET/CT imaging.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Arterial Calcification</condition>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Vitamin K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One group receives tablets of 360 microgram menaquinone-7 daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One group receives placebo tablets daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Menaquinone-7</intervention_name>
    <arm_group_label>Vitamin K</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Middle aged men and women, ≥ 40 years.

          -  Diagnosed with type 2 diabetes.

          -  Presence of arterial diseases, based on an Ankle Brachial Index (ABI) &lt;0.9 and/or
             diagnosed with arterial diseases by physician.

          -  ABI&lt;0.9

          -  Written informed consent.

        Exclusion Criteria:

          -  Subjects participate in another intervention research or study using imaging.

          -  Contra-indication for undergoing18F-NaF PET/CT scan (claustrophobia, pregnancy,
             breastfeeding).

          -  Subject underwent amputation of the lower extremities (above the knee).

          -  Using vitamin K antagonists.

          -  Known coagulation problems (history of Venous Thrombo Embolism).

          -  Using vitamin supplements that contain vitamin K, vitamin D or calcium, or unwilling
             to stop two weeks before randomisation.

          -  A mean vitamin K2 intake ≥120 microgram/day measured with a questionnaire.

          -  Natto or goose liver consumers.

          -  Low kidney function (eGFR&lt;30).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sabine Zwakenberg, Msc.</last_name>
    <phone>+31 88 7569631</phone>
    <email>s.r.zwakenberg-3@umcutrecht.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Zwakenberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 18, 2016</lastchanged_date>
  <firstreceived_date>July 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Yvonne T. van der Schouw</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Vitamin K 2</mesh_term>
    <mesh_term>Vitamin MK 7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
